Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Completed × melflufen × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1

Interventions

Cyclophosphamide 628 Cisplatin 589 Gemcitabine 557 Bevacizumab 535 Carboplatin 525 Paclitaxel 517 Docetaxel 497 Radiotherapy 483 Fluorouracil 361 Oxaliplatin 342 Rituximab 326 Capecitabine 311 Doxorubicin 308 Etoposide 285 Filgrastim 282 Irinotecan 276 Dexamethasone 272 Leucovorin 249 Cetuximab 229 pembrolizumab 225 Cytarabine 204 Bortezomib 197 Trastuzumab 192 Erlotinib Hydrochloride 190 Vincristine 187 Prednisone 187 Nivolumab 186 Pemetrexed 176 fludarabine phosphate 169 Temozolomide 168

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02963493 2022-11-22

HORIZON

Oncopeptides AB

Phase 2 Completed

157 enrolled 26 charts 1 FDA

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡